LINKER-MM1
First in Human (FIH) Study of Linvoseltamab (REGN5458) in Patients With Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 309 patients (estimated)
- Sponsors
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 4 months ago
- SparkCures ID
- 1016
- NCT Identifier
- NCT03761108
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.